A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen

Prakash Satwani; Monica Bhatia; James H. Garvin; Diane George; Filemon Dela Cruz; John Le Gall; Zhezhen Jin; Joseph Schwartz; Deirdre Duffy; Carmella van de Ven; Sandra Foley; Ria Hawks; Erin Morris; Lee Ann Baxter-Lowe; Mitchell S. Cairo

doi:10.1016/j.bbmt.2011.11.007

A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2011.11.007 ◽

2012 ◽

Vol 18 (2) ◽

pp. 324-329 ◽

Cited By ~ 20

Author(s):

Prakash Satwani ◽

Monica Bhatia ◽

James H. Garvin ◽

Diane George ◽

Filemon Dela Cruz ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Gemtuzumab Ozogamicin ◽

Myeloablative Conditioning ◽

Poor Risk

Download Full-text

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2014.02.003 ◽

2014 ◽

Vol 20 (5) ◽

pp. 730-734 ◽

Cited By ~ 11

Author(s):

Albert C. Yeh ◽

Andrew M. Brunner ◽

Thomas R. Spitzer ◽

Yi-Bin Chen ◽

Erin Coughlin ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Cell Transplantation ◽

Graft Versus Host Disease ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Urate Oxidase ◽

Graft Versus Host ◽

Acute Graft

Download Full-text

A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2013.04.013 ◽

2013 ◽

Vol 19 (7) ◽

pp. 1040-1045 ◽

Cited By ~ 9

Author(s):

Usama Gergis ◽

Gail Roboz ◽

Tsiporah Shore ◽

Ellen Ritchie ◽

Sebastian Mayer ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Leukemia ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Adult Patients

Download Full-text

Preliminary results of gemtuzumab ozogamicin (GO) during myeloablative conditioning for allogeneic stem cell transplantation (AlloSCT) or following reduced intensity alloSCT (RI-AlloSCT) in children with AML

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.7038 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 7038-7038

Author(s):

P. Satwani ◽

I. Waxman ◽

M. Bhatia ◽

Z. Jin ◽

V. Kohl ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Gemtuzumab Ozogamicin ◽

Myeloablative Conditioning ◽

Preliminary Results ◽

Reduced Intensity

Download Full-text

Faculty of 1000 evaluation for A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718008185.793479818 ◽

2013 ◽

Author(s):

Anskar Leung

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Leukemia ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Adult Patients

Download Full-text

Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2008.12.304 ◽

2009 ◽

Vol 15 (2) ◽

pp. 99 ◽

Cited By ~ 2

Author(s):

W.A. Wood ◽

C.M. Walko ◽

K.V. Rao ◽

J. Whitley ◽

D.T. Moore ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Continuous Infusion ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Hematologic Malignancies ◽

Maximum Tolerated Dose ◽

Fixed Dose

Download Full-text

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

Haematologica ◽

10.3324/haematol.2015.141176 ◽

2016 ◽

Vol 101 (10) ◽

pp. 1251-1259 ◽

Cited By ~ 10

Author(s):

S. Nikiforow ◽

H. T. Kim ◽

H. Daley ◽

C. Reynolds ◽

K. T. Jones ◽

...

Keyword(s):

Stem Cell ◽

T Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Regulatory T Cell ◽

Phase I Study ◽

Donor Lymphocyte Infusion

Download Full-text

Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study

Haematologica ◽

10.3324/haematol.11132 ◽

2007 ◽

Vol 92 (7) ◽

pp. 952-959 ◽

Cited By ~ 127

Author(s):

M. Introna ◽

G. Borleri ◽

E. Conti ◽

M. Franceschetti ◽

A. M. Barbui ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Killer Cells

Download Full-text

202: Preliminary Results of a Phase I Study of Immuno-Chemotherapy (CTX) Conditioning with Gemtuzumab Ozogamicin (GO), Busulfan (Bu) and Cyclophosphamide (Cy) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) in Pediatric Recipients with High Risk (HR) CD33+ Acute Myelogenous Leukemia (AML)

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2007.12.211 ◽

2008 ◽

Vol 14 (2) ◽

pp. 75

Author(s):

I. Waxman ◽

M. Bhatia ◽

E. Qualter ◽

Z.Z. Jin ◽

V. Kohl ◽

...

Keyword(s):

Stem Cell ◽

High Risk ◽

Stem Cell Transplantation ◽

Phase I ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Gemtuzumab Ozogamicin ◽

Myelogenous Leukemia ◽

Acute Myelogenous ◽

Pediatric Recipients

Download Full-text

Phase I Study of Brentuximab Vedotin for the Prevention of Acute GvHD after Unrelated Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2015.11.947 ◽

2016 ◽

Vol 22 (3) ◽

pp. S413

Author(s):

Mark A. Schroeder ◽

Michael P. Rettig ◽

Sarah Willey ◽

Theresa Fletcher ◽

Stephanie Meier ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase I Study ◽

Acute Gvhd ◽

Brentuximab Vedotin

Download Full-text

A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33 + Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2016.01.019 ◽

2016 ◽

Vol 22 (4) ◽

pp. 698-704 ◽

Cited By ~ 9

Author(s):

Stacey Zahler ◽

Monica Bhatia ◽

Angela Ricci ◽

Sumith Roy ◽

Erin Morris ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Study ◽

Gemtuzumab Ozogamicin ◽

Reduced Intensity Conditioning ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text